EUVIMEDEUVIMED entdecken
Crossref

Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018

Maria Choufany, Laurence Weiss, Alain Makinson, Hélène Roul, Jean-Michel Livrozet, Valérie Pourcher iD, Giovanna Melica, Christophe Rioux, Jean-Paul Viard, Esaie Marshall, Sophie Grabar iD, Dominique Costagliola iD

Clinical Infectious Diseases · 17.04.2023 · 76 (8) · 1364-1371

DOI: 10.1093/cid/ciac939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.12.2022. Verfasst von Maria Choufany und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris F75013, France. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Agence Nationale de Recherche sur le Sida et les Hépatites Virales–Maladies Infectieuse Emergentes, Institut National de la Santé et de la Recherche Médicale, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A previous study showed an association between CD4 T-cell count decline in people with human immunodeficiency virus infection (PWH) with viral suppression and an increased risk of severe morbid conditions. We aimed to assess the risk of CD4 T-cell count decline (hereafter, CD4 decline), determine associated factors, and evaluate the association of this decline with the risk of severe morbid conditions (cardiovascular disease and cancer) or death.

Methods

From the Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) CO4 French Hospital Database on HIV cohort, we selected PWH >18 years old who had been followed up for ≥2 years after viral suppression following the initiation of combination antiretroviral therapy (cART) between 2006 and 2018. CD4 decline was defined as 2 consecutive relative differences ≥15%. Among participants with such decline, we modeled CD4, CD8, and total lymphocyte counts before and after CD4 decline, using spline regression. The remaining objectives were assessed using Poisson regression, with the association between CD4 decline and the risk of severe morbid conditions or death evaluated during or after 6 months of decline.

Results

Among 15 714 participants (75 417 person-years), 181 presented with CD4 decline (incidence rate, 2.4/1000 person-years (95% confidence interval, 2.1–2.8). CD8 and total lymphocyte counts also showed a similar decline. Older current age and lower viral load at treatment initiation were associated with the risk of CD4 decline. The risk of severe morbid conditions or death was 11-fold higher during the first 6 months for participants who presented with CD4 decline versus those who did not (incidence rate ratio, 10.8 [95% confidence interval, 5.1–22.8]), with no significant difference after 6 months.

Conclusions

In PWH with viral suppression, CD4 decline was rare and related to global lymphopenia. It was associated with a higher risk of severe morbid conditions or death during the first 6 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansAdolescentAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesViral LoadCD4 Lymphocyte Count

Stichwörter der Autor:innen

CD4 declineHIVPWHcohort studysevere morbidity

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris F75013, France.
  • Clinical Immunology Department, Hôtel Dieu Hospital, AP-HP, INSERM U1016 - CNRS UMR8104, Institut Cochin, Université Paris Cité, Paris, France.
  • University of Montpellier, INSERM U1175, Montpellier, France.
  • Department of Infectious and Tropical Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
  • Department of Infectious and Tropical Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
  • Infectious Diseases Department, Henri-Mondor/Albert-Chenevier Hospital Group, Créteil, France.

ORCID-Profile: Valérie Pourcher, Sophie Grabar, Dominique Costagliola

Förderung

  • Agence Nationale de Recherche sur le Sida et les Hépatites Virales–Maladies Infectieuse Emergentes
  • Institut National de la Santé et de la Recherche Médicale
  • Ministry of Health

Zitieren

APA

Choufany, M., Weiss, L., Makinson, A., Roul, H., Livrozet, J. M., Pourcher, V., Melica, G., Rioux, C., Viard, J. P., Marshall, E., Grabar, S., & Costagliola, D. (2023). Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018. Clinical Infectious Diseases, 76(8), 1364-1371. https://doi.org/10.1093/cid/ciac939

Vancouver

Choufany M, Weiss L, Makinson A, Roul H, Livrozet JM, Pourcher V, et al. Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018. Clinical Infectious Diseases. 2023;76(8):1364-1371. doi:10.1093/cid/ciac939

BibTeX
@article{Choufany2023,
  author = {Choufany, Maria and Weiss, Laurence and Makinson, Alain and Roul, Hélène and Livrozet, Jean-Michel and Pourcher, Valérie and Melica, Giovanna and Rioux, Christophe and Viard, Jean-Paul and Marshall, Esaie and Grabar, Sophie and Costagliola, Dominique},
  title = {Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {8},
  pages = {1364--1371},
  doi = {10.1093/cid/ciac939}
}
Kostenlos starten →